Product Description: Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]O V Boyko, et al. Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(10. Vyp. 2):87-95.